In the REDEFINE 1 phase 3 trial (NCT05567796), which enrolled adults with overweight or obesity (BMI 27 kg/m) and at least 1 weight-related comorbidity but without type 2 diabetes, participants receiving CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg) achieved a mean body weight reduction of 22.7% from baseline after 68 weeks among adherent participants, compared with approximately 3% in the placebo group.5 These results establish CagriSema as one of the most potent antiobesity therapies investigated to date
Founded on May 10, 1876, Eli Lilly now has over 44,000 employees and markets its products in over 100 countries around the world
Wegovy dosing schedule and what to expect Managing side effects and tips that work Pricing, delivery, and how to get started Why Protein Matters When Taking GLP-1 Medications GLP-1 receptor agonists, such as semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda, Victoza), are increasingly prescribed in the UK for type 2 diabetes management and weight loss
The All of Us Research programme supplied patient data for this analysis
Wegovy dosing schedule and what to expect Managing side effects and tips that work Pricing, delivery, and how to get started Potential Risks and Drug Interactions When Combining Weight Loss Medications Combining weight loss medications carries inherent risks that extend beyond the known side effect profiles of individual drugs
